480439-44-9Relevant articles and documents
ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH P13K MODULATION
-
Paragraph 1139; 1162, (2021/10/11)
The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I), or a prodrug, solvate, enantiomer, st
Successful development and scale-up of a palladium-catalysed amination process in the manufacture of ZM549865
Robinson, Graham E.,Cunningham, Oliver R.,Dekhane, Mouloud,McManus, Julie C.,O'Kearney-McMullan, Anne,Mirajkar, Abdurrazzaque M.,Mishra, Vikas,Norton, Alison K.,Venugopalan,Williams, Emyr G.
, p. 925 - 930 (2013/09/03)
Key steps in the synthesis of ZM549865 (a 5-HT receptor antagonist) are the palladium-catalysed amination of ethyl 8-bromo-6-fluoro-4-oxo-4H-2- chromenecarboxylate and subsequent hydrolysis of the ester group. The development of a simple, robust process c